CYP2R1

Some people stay stubbornly low on vitamin D no matter how much sun they get, how clean they eat, or how many capsules they swallow. The explanation often sits in their DNA, in a gene called CYP2R1 (cytochrome P450 family 2 subfamily R member 1) that builds the liver enzyme responsible for the first activation step of vitamin D.

This test reads your CYP2R1 variants once, and those results stay relevant for life. It can help explain stubborn deficiency, predict how readily your vitamin D level will respond to supplementation, and reveal a small but real contribution to your risk for a handful of conditions, particularly multiple sclerosis and type 1 diabetes.

What CYP2R1 Actually Does

Vitamin D from sunlight, food, and supplements is biologically inert until your body activates it in two steps. The first step happens mostly in your liver, where the enzyme made by CYP2R1 converts vitamin D into 25-hydroxyvitamin D, the standard form measured on a vitamin D blood test. A second step in your kidneys turns that into the fully active hormone.

CYP2R1 is the main bottleneck for that first conversion. Rare loss-of-function mutations in CYP2R1 cause a genetic condition called vitamin D-dependent rickets type 1B, in which 25-hydroxyvitamin D stays very low despite adequate sun and oral vitamin D, while the active kidney-made form can look surprisingly normal. More common, milder CYP2R1 variants nudge baseline 25-hydroxyvitamin D up or down and shape how readily it rises with treatment.

This test belongs in the small but growing category of genetic tests that explain a measurable trait. It is a research-grade marker rather than a guideline-endorsed screening tool. There are no consensus thresholds telling you which variant combinations require action, but the gene's role in vitamin D biology is well established and the same genotype follows you for life.

Why Your Genotype Influences Vitamin D Levels

Large genetic studies of European-ancestry adults have repeatedly identified CYP2R1 as one of the strongest inherited influences on circulating 25-hydroxyvitamin D, alongside the gene that codes for vitamin D's main blood carrier protein. The same finding shows up in Caucasian, Danish, Finnish, Saudi, Tunisian, and East Asian cohorts, which means the effect is not population-specific.

In a U.S. family-practice cohort, carriers of certain CYP2R1 risk alleles had roughly 3.7 times higher odds of being vitamin D deficient than non-carriers. A study of healthy Danish families found that people with combined high-risk CYP2R1 and carrier-protein haplotypes ran 25-hydroxyvitamin D levels several nanograms per milliliter lower than people with the low-risk profile, even in late summer. The size of these gene effects is large enough to push someone from sufficient into deficient territory under otherwise identical conditions.

Population genetics adds another wrinkle. A functional screen of 44 naturally occurring nonsynonymous CYP2R1 variants found that many reduce enzyme activity, and the low-activity alleles are more common in populations historically exposed to high sunlight. That pattern is consistent with evolutionary pressure to throttle vitamin D activation in equatorial regions, which means your inherited CYP2R1 profile may reflect where your ancestors lived more than what your body needs today.

Bone Disease and Skeletal Health

The clearest skeletal signal comes from people with two damaged copies of CYP2R1. Case series of children with vitamin D-dependent rickets type 1B describe very low 25-hydroxyvitamin D, low calcium and phosphate, and classic rickets despite normal sun exposure or routine vitamin D doses. These patients often need 25-hydroxyvitamin D itself rather than ordinary vitamin D, because their bottleneck is the activation step the supplement is meant to bypass.

Common CYP2R1 variants are also tied to bone density. In a Swedish study of about 2,900 older men, certain CYP2R1 haplotypes lined up with both 25-hydroxyvitamin D levels and bone mineral density, although the relationship with other bone metabolism markers was not consistent. In Finnish toddlers, CYP2R1 haplotypes shifted 25-hydroxyvitamin D and tracked with skeletal measurements at age two.

There is a curious counter-finding worth knowing about. A small follow-up of adults with confirmed CYP2R1 loss-of-function mutations and lifelong low 25-hydroxyvitamin D found their bone mineral density was not impaired. This does not contradict the bigger picture so much as refine it: the rare monogenic form may be partially compensated by other pathways once the skeleton is mature, while milder common variants still appear to drift bone density downward at the population level. Treat CYP2R1 as a contributor to bone risk rather than a standalone verdict.

Type 1 Diabetes

CYP2R1 variants associate with type 1 diabetes risk. An early German case-control study of about 600 adults found polymorphisms in CYP2R1 linked to both lower vitamin D levels and higher odds of type 1 diabetes. A much larger genetic analysis of more than 24,000 participants confirmed the link, with inherited variation in CYP2R1 and a related gene (DHCR7) consistently associated with type 1 diabetes. The effect per person is small, but the consistency across studies is what makes it credible.

None of this means a high-risk CYP2R1 genotype causes type 1 diabetes. It contributes to a risk profile in the same way other low-penetrance variants do. If you carry one of these alleles and have a family history of autoimmune disease, your vitamin D status becomes more worth tracking, not less.

Multiple Sclerosis

A large international genetic study used a low-frequency CYP2R1 coding variant called rs117913124 to test whether genetically low vitamin D actually drives multiple sclerosis, rather than just sitting alongside it. Carriers had about 2.2 times the odds of vitamin D insufficiency and roughly 40% higher odds of multiple sclerosis. Because the variant is inherited at conception, this design rules out reverse causation and supports a real causal link between the vitamin D pathway and multiple sclerosis risk.

The same approach has been tried for many other conditions and most have not held up. The multiple sclerosis result has.

Cardiovascular and Metabolic Risk

A smaller body of work has tied CYP2R1 variants to cardiovascular disease, metabolic syndrome, and obesity-related vitamin D deficiency. A 2025 Spanish case-control study of 766 adults flagged the CYP2R1 variant rs10741657 as a potential cardiovascular risk marker. A 2025 pilot study of 53 cardiovascular patients found CYP2R1 polymorphisms tracked with their vitamin D metabolite profile. Animal and human tissue work also shows that obesity itself suppresses CYP2R1 in the liver and other organs, which may be one reason vitamin D levels run low in people with higher body fat.

A Mendelian randomization study in nearly 6,000 people did not find that genetically lower 25-hydroxyvitamin D causes type 2 diabetes, even though observational studies have long suggested a link. This sounds like a contradiction but is not. It means low vitamin D in people with type 2 diabetes is probably a side effect of the metabolic problems rather than the cause. The same logic applies to your CYP2R1 result: a high-risk profile is a real driver of low 25-hydroxyvitamin D, but treating that low number will not necessarily protect you from every disease the number happens to track with.

How CYP2R1 Variants Shape Your Response to Supplements

A randomized trial of 1,787 adults taking 1,000 IU of vitamin D3 daily found that variation in CYP2R1 measurably changed how much 25-hydroxyvitamin D rose on the same dose. A separate Iranian study of 253 adults showed that carriers of the common G allele at a specific CYP2R1 marker had a larger increase in serum vitamin D after supplementation than non-carriers. A Tunisian study in healthy adults reached a similar conclusion using different CYP2R1 markers.

What this means for you: if you carry low-response CYP2R1 alleles and your 25-hydroxyvitamin D barely budges after months of standard supplementation, you may need a higher dose, a longer course, or in rare loss-of-function cases, the 25-hydroxyvitamin D form of vitamin D rather than ordinary vitamin D3.

Tracking Your Vitamin D Over Time

Your CYP2R1 genotype does not change, so you only need to test the gene once. The companion you should track is 25-hydroxyvitamin D, the blood marker your CYP2R1 enzyme actually produces. Knowing your genotype upfront tells you whether your 25-hydroxyvitamin D trajectory is what you would expect on a given dose of sun and supplements, or whether your biology is fighting you and a different strategy is needed.

A reasonable rhythm is: get the CYP2R1 test once for a permanent baseline, check 25-hydroxyvitamin D at the same time as a reference point, retest 25-hydroxyvitamin D 3 to 6 months after any change in supplementation or sun exposure, and then check it at least annually. If you carry a low-response genotype and you are working to raise your level, retest 25-hydroxyvitamin D after each dose change rather than waiting a year to find out whether it worked.

What an Unexpected Result Should Make You Do

A high-risk CYP2R1 result is most useful in combination with a 25-hydroxyvitamin D measurement. If both flag a problem, the pattern points to a genuine reduced capacity to convert vitamin D, and your next step is to optimize 25-hydroxyvitamin D with a more aggressive supplementation strategy and to track it tightly. If your CYP2R1 result is high-risk but your 25-hydroxyvitamin D is already healthy, your dose or your skin's production has compensated; keep doing what you are doing and retest annually.

If you carry biallelic loss-of-function mutations (extremely rare) or you have unexplained, severe, treatment-resistant vitamin D deficiency or rickets-like symptoms despite high-dose supplementation, this is the moment to involve an endocrinologist. Vitamin D-dependent rickets type 1B is treatable, but only if it is recognized. For everyone else, the practical pathway is to use your CYP2R1 result to set expectations for how much vitamin D you actually need, and to combine the genotype with serial 25-hydroxyvitamin D readings, calcium, and parathyroid hormone if your numbers do not line up.

When Results Can Be Misleading

Because CYP2R1 testing reads DNA rather than a fluctuating blood level, common confounders for blood tests (fasting, time of day, recent meals, acute illness) do not apply. The main sources of misleading interpretation are different.

• Variant coverage: different labs test different sets of CYP2R1 variants, so a normal result on one panel does not always rule out clinically relevant variants tested elsewhere.
• Sample contamination: for buccal swab tests, recent food, drink, or tobacco can interfere with DNA quality. Wait at least 30 minutes after eating, drinking, or smoking before collecting the sample.
• Genotype without phenotype: a high-risk CYP2R1 profile does not guarantee low vitamin D, and a low-risk profile does not guarantee normal vitamin D. Sun exposure, body fat, liver health, and intake all matter. The genotype is a risk modifier, not a verdict.
• Population-specific risk estimates: most published effect sizes come from European-ancestry cohorts. The biology is the same across populations but the risk numbers may not transfer directly.